HI
Medical - Equipment & Services
Bullish sentiment
Hims & Hers dominates the tape on a roughly 100% rally off March lows, driven by an FDA peptide advisory meeting scheduled for July 23-24 that bulls say could unlock a $2.2B telehealth peptide market, with Leerink estimating Hims could capture about $440M of it. Catalysts stack up: Barclays raised its price target to $39 from $29, CEO Andrew Dudum teased an Oura Ring wearable integration, the Eucalyptus international acquisition closed, and short interest sits near 30% of float fueling squeeze talk. A cautious minority warns the stock looks extended into the 200-day moving average and flags a possible bear flag.
Driven by hype
Hims & Hers is the telehealth subscription brand that scaled on hair-loss, ED, and weight-loss prescriptions — and is now trying to become a more durable virtual-care platform. The stock has just doubled off the lows on a short-squeeze setup and FDA-meeting hype, but the most recent quarter showed the operating model wobbling.
• The squeeze is the proximate driver: roughly 30% of float is short with a four-day cover ratio, Barclays just bumped its target to $39, and shares ran ~100% off $15 — real setup, but mechanical, not fundamental.
• Q1 2026 gross margin collapsed from 72% to 49% quarter-over-quarter and op margin flipped negative — a swing too big to be noise, and management has not cleanly explained what changed in the compounded-GLP-1 mix.
• Insiders sold meaningfully into the rally: CEO Andrew Dudum took $2.6M off via in-kind tax withholding at $30, and officers including Mohamed Elshenawy and Soleil Boughton unloaded another ~$5M combined in mid-June.
• A 0% coupon convertible due 2032 and a pending acquisition (Amendment No. 3 to the JPMorgan credit line) say management is using a stretched share price to fund deals rather than buy back stock — not a sign of conviction at this price.
The July 23 FDA peptide meeting is the binary that decides this — a favorable read reignites the squeeze; an unfavorable read against the Q1 margin slip is where the 100% round-trip starts, and the August 10 Q2 print is the second test.
